Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Abramson Cancer Center of the University of Pennsylvania Identifier:
First received: August 8, 2005
Last updated: February 17, 2016
Last verified: May 2007

RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B), can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for glioblastoma multiforme.

PURPOSE: This phase I trial is studying the side effects and best dose of ^131I MOAB TNT-1/B in treating patients with progressive or recurrent glioblastoma multiforme.

Condition Intervention Phase
Brain and Central Nervous System Tumors
Radiation: iodine I 131 monoclonal antibody TNT-1/B
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Dose Confirmation and Dosimetry Study of Interstitial 131 I-chTNT-1/B MAb (COTARA(TM)) For the Treatment of Glioblastoma Multiforme (GBM) at 1st or 2nd Relapse

Resource links provided by NLM:

Further study details as provided by Abramson Cancer Center of the University of Pennsylvania:

Primary Outcome Measures:
  • Maximum tolerated dose based on CTCAE v3.0 weekly for 8 weeks then every 8 weeks

Secondary Outcome Measures:
  • Biodistribution and radiation dosimetry by blood, urine, and whole body scans daily for 10 days
  • Toxicity by CTCAE v3.0 weekly for 12 weeks then every 8 weeks
  • Overall survival, median time of survival, and percent alive at 6 months

Estimated Enrollment: 22
Study Start Date: October 2005
Study Completion Date: October 2007
Detailed Description:



  • Determine the maximum tolerated dose of iodine I 131 monoclonal antibody TNT-1/B in patients with progressive or recurrent glioblastoma multiforme.


  • Determine the biodistribution and radiation dosimetry of this drug in these patients.
  • Determine the toxicity and tolerability of this drug in these patients.
  • Determine the overall survival, median time of survival, and 6-month survival of patients treated with this drug.

OUTLINE: This is an open-label, multicenter, dose-escalation study of therapeutic doses of iodine I 131 monoclonal antibody TNT-1/B (^131I MOAB TNT-1/B).

The first 12 patients accrued to the study undergo stereotactic placement of 2 catheters within the contrast-enhancing tumor on day 0. These patients then receive an imaging dose of ^131I MOAB TNT-1/B interstitially over approximately 25 hours on day 1 followed by dosimetry, biodistribution evaluations, and whole body imaging over an 8-10 day period. Beginning at least 2 weeks, but no more than 4 weeks later, all patients undergo catheter placement as above. One day later, patients receive a therapeutic dose of ^131I MOAB TNT-1/B interstitially over approximately 25 hours.

Cohorts of 3-6 patients receive escalating therapeutic doses of ^131I MOAB TNT-1/B until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 10 patients are treated at the MTD.

After completion of study treatment, patients are followed weekly for 3 weeks, at 6 weeks, at 4, 8, and 12 weeks (for the first 12 patients accrued to the study), every 4 weeks until disease progression, and then every 8 weeks thereafter.

PROJECTED ACCRUAL: Approximately 22 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed glioblastoma multiforme

    • Focal disease
    • Progressive or recurrent disease after prior treatment with radiotherapy and/or chemotherapy
    • Low-grade astrocytoma that progressed to glioblastoma multiforme after prior radiotherapy and/or chemotherapy allowed
  • Gross tumor volume 5-60 mL
  • No intraventricular tumor, infratentorial tumor, or tumor that communicates with the ventricles
  • No bilateral non-contiguous gadolinium-enhancing tumor
  • No diffuse disease, defined as any satellite lesion > 1.5 cm from the anticipated location of a catheter tip OR > 2 satellite lesions
  • No ventricular invasion outside the anticipated radiotherapy volume



  • 18 and over

Performance status

  • Karnofsky 60-100%

Life expectancy

  • Not specified


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL


  • Bilirubin ≤ 1.5 mg/dL
  • AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Hepatitis B negative
  • No evidence of active hepatitis


  • Creatinine ≤ 1.7 mg/dL
  • BUN ≤ 2 times ULN


  • No uncontrolled hypertension
  • No unstable angina pectoris
  • No uncontrolled cardiac dysrhythmia


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Able to undergo MRI
  • Mini Mental State Exam score ≥ 15
  • No serious infection
  • No other medical illness that would preclude study participation
  • No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer
  • No psychological or sociological condition, addictive disorder, or other condition that would preclude study compliance
  • No known or suspected allergy to study drug or iodine
  • No known HIV positivity


Biologic therapy

  • No prior monoclonal antibodies
  • No prior local immunotherapy or treatment with the following biologic agents:

    • Immunotoxins
    • Immunoconjugates
    • Antiangiogenesis compounds
    • Antisense agents
    • Peptide receptor antagonist
    • Interferons
    • Interleukins
    • Tumor infiltrating lymphocytes
    • Lymphokine-activated killer cells
    • Gene therapy


  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
  • At least 3 months since prior polifeprosan 20 with carmustine implant (Gliadel wafer^® )

Endocrine therapy

  • Must be maintained on a stable corticosteroid dose (approximately 4 mg) for ≥ 2 weeks before study entry


  • See Disease Characteristics
  • At least 3 months since prior radiotherapy
  • No prior brachytherapy or radiosurgery


  • At least 4 weeks since prior surgery


  • Recovered from all prior therapy
  • At least 1 month since prior investigational agents
  • No more than 2 prior treatment regimens
  • No other prior local therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00128635

United States, Alabama
Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham
Birmingham, Alabama, United States, 35294
United States, Georgia
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States, 30322
United States, North Carolina
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104-4283
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)
Study Chair: Robert A. Lustig, MD Abramson Cancer Center of the University of Pennsylvania
OverallOfficial: Kevin Judy, MD Abramson Cancer Center of the University of Pennsylvania
  More Information Identifier: NCT00128635     History of Changes
Other Study ID Numbers: CDR0000438768
Study First Received: August 8, 2005
Last Updated: February 17, 2016

Keywords provided by Abramson Cancer Center of the University of Pennsylvania:
adult glioblastoma
adult gliosarcoma
adult giant cell glioblastoma
recurrent adult brain tumor

Additional relevant MeSH terms:
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms by Site
Nervous System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Anti-Infective Agents, Local
Anti-Infective Agents
Trace Elements
Growth Substances processed this record on May 25, 2017